ImmunityBio heads into its June 9 earnings report caught between two opposing forces: options traders have turned sharply bullish on a three-day basis, yet a deeply entrenched short position covering more than a third of the free float refuses to budge.
The lending market tells a story of a heavily-crowded short. Short interest has barely moved over three months — from around 34.1% of the free float in mid-February to 35.0% today — a stubborn, sticky position that has weathered the stock's explosive year-to-date run. Availability has tightened sharply over the past 24 hours: where it was sitting near 17–18% earlier this week, it dropped to just under 8% on May 19 — well inside "very tight" territory, meaning roughly one share is still available for every twelve already borrowed. The ORTEX short score of 77 puts the stock in the most elevated tier of short-side pressure across the universe, and the days-to-cover reading of 10.6 means that if shorts needed to exit in size, it would take two full trading weeks at average volume. Cost to borrow has eased considerably — down 47% over the past month from a peak above 10% to 4.5% now — suggesting short sellers are not scrambling to pay up for borrows, but the structural tightness in availability means the lending pool has little room left.
The options market paints a different picture entirely. Call positioning has dominated, with the put/call ratio at 0.31 — more than two standard deviations below its 20-day average of 0.34 and near the low end of its 52-week range of 0.20–0.42. That reading signals the most bullish skew in options in weeks, right as the stock has slipped 4.4% on the week to $7.76. The divergence is notable: equity has weakened while options traders added call exposure. This is the central tension heading into the June 9 print.
The analyst community is uniformly constructive but covering a wide spread of conviction. HC Wainwright reiterated its Buy with a $15 target on May 20 — exactly a week before this note. BTIG assumed coverage with Buy and a $13 target in March. D. Boral Capital has repeatedly held at Buy with a $23 target. The mean consensus sits at $15.25 against a current price of $7.76, implying near-doubling to get there. The bull case rests on ANKTIVA commercialization — a real approval, a real asset — plus expansion into NSCLC and the cushion provided by a recent $100M financing package. Bears point to IBRX's still-minimal revenue, deeply negative earnings (the P/E ratio is -17.3, earnings yield -5.8%), and the execution gap between regulatory win and sustainable cash flow. EPS momentum has been exceptional — ranking in the 99th percentile on the 30-day reading and 96th over 90 days — but EPS here is measured against a very low bar. The company's quality and value factor scores remain weak, consistent with a pre-profitability biotech.
Ownership is highly concentrated at the top. Founder and Chief Medical Officer Patrick Soon-Shiong holds 27.8% of shares directly, with California Capital Equity adding another 24.7%. Together with NantWorks at 9.4%, the founder-affiliated bloc controls over 60% of the company. Passive giants Vanguard and BlackRock recently added modestly to positions. D. E. Shaw built a new 1.2% stake as of March 31 — a quant firm's entry in a heavily-shorted name is a detail worth tracking. The most recent insider activity, from late February, was net selling: an Executive Director disposed of roughly $2.6M across two days near $10–12, the CFO sold a smaller amount, and the founder himself sold 58,170 shares at $8.70 around the same time. No insider buying has been recorded since.
Past earnings prints for IBRX have been volatile and unpredictable. A May 8 event produced a 4.5% one-day gain but faded to a modest 2.7% five-day move. A March 3 event brought a 13.8% drop on the day, extending to a 23.3% five-day loss. The stock does not have a reliable post-earnings direction — it has gone both ways sharply. With short interest at 35% of the float and availability this tight, a positive catalyst could compress an already thin lending pool quickly. The reverse is equally plausible: a revenue miss against a $23 analyst target stretches credibility for even the most committed bulls.
The June 9 print is therefore less a referendum on the ANKTIVA thesis — already largely priced in at current short interest levels — and more a test of whether IBRX can show the revenue ramp that would justify the call-heavy options positioning going into it.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
